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Figure 1. Specimen Source of 140 Clinical  
Isolates Collected from Misrata, Libya.
Figure 2.  Bacterial species distribution of the 140 
Clinical Isolates. 
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Figure 3. Distribution of 34 Carbapenem resistant 
Gram negative bacilli isolated.
% of resistance IMI MER DOR ERT AMI AZT CAZ CPM CTX TZP T-C DOX MIN TIG** GEN CIP TOB LEV SXT CO**
K. pneumoniae
(n=25)
100% 88% 76% 100% 12% 88% 88% 88% 96% 100% 100% 80% 68% 04% 84% 100% 92% 76% 88% 0%
P. aeruginosa      
(n= 3)
33% 0 % 100% * 33% 33% 33% 33% * 100% 100% * * * 66.5% 66.5% 66.5% 100% * 0%
P. mirabilis                       
(n=2)
100% 100% 100% 100% 50% 50% 50% 50% 100% 100% 100% * * * 50% 50% 50% 50% 50% *
E. coli
(n=2)
0% 50 % 50% 100 % 100% 0% 100% 100% 100% 100% 100% 100% 100% 0% 100% 100% 100% 100% 100% 0%
Cit. koseri
(n=1)
100% 100% 100% 100% 0% 0% 0% 0% 100% 100% 100% 0% 0% 0% 0% 0% 0% 0% 0% 0%
R. aquatilis
(n=1)
100% 100% 100% 100% 0% 0% 0% 0% 100% 100% 100% 100% 100% 0% 0% 0% 0% 100% 100% 0%
Table 1. Carbapenem resistance of Gram-negative bacilli.
Conclusions
Mohamed Shallouf, Pedro MDS Abrantes, Charlene WJ Africa
Microbial Endogenous Infections (MEnIS) Research Laboratories, Department of Medical 
Biosciences, University of the Western Cape, Private Bag X17, Bellville 7535, South Africa 
mohamed.shallouf@gmail.com
18%
29%
23%
15%
15%
Figure 4. Distribution of various types of 
β-lactamases detected. 
Metallo β-lactams (MBL)
K. pneumoniae
carbapenemase (KPC)
Class D β-lactams (OXA-
48)
AmpC  β-lactams+ porin 
loss
MBL+KPC
IMI: Imipenem; MER: Meropenem; DOR; Doripenem; ERT; Ertapenem; AMI; Amikacin; AZT; Azteroname; CAZ; Ceftazidime; CPM;  Cefepim; CTX Cefotaxime; TZP: Pipracillin/ tazobactam;  T-C: 
Ticarcillin/Clavulanic acid; DOX: Doxycycline; MIN: Minocycline; TIG: Tigecycline; GEN: Gentamicin; CIP: Ciprofloxacin; TOB: Tobramycin; LEV: Levofloxacin; SXT: 
Trimethoprim/Sulphamethoxazole; CO: Colistin. 
* Intrinsic resistance, ** EUCAST breakpoints
Abstract
Background: Carbapenem resistance among Gram-negative bacilli has emerged as a public health concern since they raise the threat of untreatable infections. Despite reports of
Carbapenemase producing Gram-negative bacilli in several countries over the world, there is a lack of data about their presence in Libya. Therefore, this study was pursued to identify the
presence of carbapenemase-producing Gram-negative bacilli isolated from Libyan patients.
Methods: Bacterial species were collected from hospitals and pathology laboratories in Misrata, Libya. Growth characteristics and API 20E or API 20NE biochemical testing systems were used
to identify the bacterial isolates. Screening for carbapenem resistance was performed using the disk diffusion method, and minimum inhibitory concentrations (MIC) were determined using the
Sensititre Gram-negative Xtra plate format (GNX2F). All strains demonstrating resistance or intermediate susceptibility to one of the four carbapenems were subjected to carbapenemase
activity detection using the RAPIDEC CARBA NP test, Modified Hodge test (MHT), carbapenem inactivation methods (CIM), Carbapenemase detection kit (D70C Set) with Temocillin
(TEM)30µg from MAST group and combined meropenem-Ethylenediaminetetraacetic acid (EDTA) and/or phenylboronic acid (PBA) disks.
Results and conclusion: Of the 140, 34 (24.3%) isolates were carbapenemase-producers of which 25 (73%) were K. pneumoniae. These findings emphasize the crucial need for accurate
screening, identification and susceptibility testing to prevent further spread of nosocomial and community acquired resistance.
- The 24.3% rate of carbapenem-resistant Enterobacteriaceae and other Gram-negative bacilli seen in this
study showed a high and worrisome trend.
- The findings of this study highlight the vital need for accurate screening and susceptibility testing to
prevent further spread of nosocomial and community acquired resistance. This may be achieved through
the establishment of antibiotic stewardship programmes along with firm infection control practices.
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Aim of study
The aim of this study was to obtain a better understanding of carbapenem
resistant Enterobacteriacea (CRE) strains prevalent in Libyan patients by
investigating their phenotypic characteristics and antibiograms.
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Introduction
Carbapenemases, a group of clinically significan β-lactamases capable of
hydrolysing most β-lactams, including carbapenems, have emerged and
spread among members of Enterobacteriaceae and other Gram-negative
bacilli worldwide, leaving fewer therapeutic options and creating a public
health concern. The exact occurrence of Carbapenemase-producing bacteria
in healthcare settings and within the community in Libya is still uncertain.
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- K. pneumoniae contributed to the vast majority of carbapenem resistant Gram -negative bacilli followed 
by  E. coli and P. mirabilis.
- Coexistence of KPC and MBL were found in  five isolates (15%), with KPC being the most frequent type 
of β-lactamases followed by OXA-48 and MBL.
